Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Urrutia Gajate (Bilbao (Bizkaia), Spain), A. Rezola Carasusan (Bilbao (Bizkaia), Spain), B. Ortiz De Urbina (Bilbao (Bizkaia), Spain), M. Garcia Moyano (Bilbao (Bizkaia), Spain), R. Zalacain Jorge (Bilbao (Bizkaia), Spain), L. Ruiz Iturriaga (Bilbao (Bizkaia), Spain), L. Serrano Fernandez (Bilbao (Bizkaia), Spain), C. Jaca Michelena (Bilbao (Bizkaia), Spain), B. Gomez Crespo (Bilbao (Bizkaia), Spain). Hypersentivity pneumonitis in an Interstitial Lung Disease Unit, 5 years’ experience. 1805

Member's Comments

No comment yet.

Related content which might interest you: The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic. Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Combined pulmonary fibrosis and emphysema: A report from the Hellenic Interstitial Lung Diseases group Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Romanian Registry for Interstitial Lung Diseases (REGIS): inclusion of patients in 3 years Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Unclassifiable Interstitial Lung Disease (ILD). Why? Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Gender perspective in Interstitial Lung Diseases (ILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Value of community based Pulmonary Rehabilitation (PR) for patients with Interstitial Lung Disease (ILD): A retrospective review Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Translation and validation of the King's brief interstitial lung disease (K-BILD) questionnaire in French, Italian and Dutch Source: International Congress 2014 – ILDs 2 Year: 2014 Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 A Comparison of Pulmonary Rehabilitation Outcomes in Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Live patient and partner survey on pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Dedicated Pulmonary Rehabilitation for Patients with Interstitial Lung Disease in a District General Hospital Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Case Series of COVID-19 Disease in Pediatric Chronic Lung Diseases Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Lung Cancer Screening Programs: a missed “window” to diagnose Obstructive Lung Disease. The NLST-ACRIN experience. Source: International Congress 2018 – Interdependence of COPD and comorbidities and the underlying mechanisms Year: 2018 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Evaluation of three dyspnea questionnaires in the progression of Interstitial Lung Diseases. Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Inmunosuppresor therapy effectivness in Interstitial Lung Disease (ILD) associated Connective Tisuue Disease(CTD). Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017